Patheon N.V. is a leading drug contract development and manufacturing organization.

According to the Complaint, it is alleged that on May 31, 2017, in order to convince Patheon shareholders to tender their shares, the Board authorized the filing of a materially incomplete and misleading Schedule 14D-9 Solicitation/Recommendation Statement with the Securities and Exchange Commission. In particular, the Recommendation Statement contains materially incomplete and misleading information concerning Patheon’s financial projections and the valuation analyses performed by the Company’s financial advisor, Morgan Stanley & Co. LLC.

On July 21, 2017, this case was voluntarily dismissed pursuant to a Stipulation by the parties. On September 8, the Court issued an order terminating the action.